Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

Abstract Background The coronavirus disease 19 (covid-19) pandemic has underscored the need to expedite clinical research, which may lead investigators to shift away from measuring patient-important outcomes (PIO), limiting research applicability. We aim to investigate if randomized controlled trial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mario A. Jimenez-Mora, Andrea Ramírez Varela, Jose F. Meneses-Echavez, Julia Bidonde, Adriana Angarita-Fonseca, Reed A. C. Siemieniuk, Dena Zeraatkar, Jessica J. Bartoszko, Romina Brignardello-Petersen, Kimia Honarmand, Bram Rochwerg, Gordon Guyatt, Juan José Yepes-Nuñez
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Patient-important outcome Reporting Treatment Prevention Coronavirus Covid-19 Medicine R
Acceso en línea:	https://doaj.org/article/4ad1c46a4def4d14a7cd3c8366c1070a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

Ejemplares similares